OptimizeRx Co. (NASDAQ:OPRX) Receives $9.06 Average Target Price from Analysts

OptimizeRx Co. (NASDAQ:OPRX) has received an average recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1-year target price among brokers that have covered the stock in the last year is $9.06.

OPRX has been the topic of several recent analyst reports. JMP Securities reaffirmed a “market outperform” rating and set a $8.00 price objective on shares of OptimizeRx in a report on Thursday, February 6th. Lake Street Capital reaffirmed a “buy” rating and issued a $11.00 price target on shares of OptimizeRx in a research note on Tuesday, December 24th. Stifel Nicolaus cut their price objective on OptimizeRx from $13.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday, November 14th. Barclays reduced their target price on OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating for the company in a report on Thursday, November 14th. Finally, William Blair reaffirmed an “outperform” rating on shares of OptimizeRx in a research note on Thursday, November 14th.

OptimizeRx Trading Down 3.8 %

Shares of NASDAQ:OPRX opened at $5.56 on Friday. The business’s 50 day moving average price is $5.44 and its 200-day moving average price is $6.20. OptimizeRx has a 1 year low of $3.78 and a 1 year high of $16.65. The firm has a market capitalization of $102.42 million, a price-to-earnings ratio of -4.18 and a beta of 1.38. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.23 and a quick ratio of 3.23.

Insider Transactions at OptimizeRx

In related news, CEO William J. Febbo bought 20,000 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was acquired at an average cost of $5.01 per share, with a total value of $100,200.00. Following the purchase, the chief executive officer now directly owns 601,253 shares of the company’s stock, valued at $3,012,277.53. The trade was a 3.44 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets raised its stake in OptimizeRx by 189.2% during the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock worth $28,000 after purchasing an additional 2,414 shares during the period. SBI Securities Co. Ltd. acquired a new stake in shares of OptimizeRx during the 4th quarter worth approximately $25,000. Quest Partners LLC raised its position in shares of OptimizeRx by 15,965.6% during the 3rd quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock valued at $76,000 after buying an additional 9,739 shares during the period. SG Americas Securities LLC purchased a new stake in shares of OptimizeRx during the 4th quarter valued at approximately $51,000. Finally, Wells Fargo & Company MN grew its position in OptimizeRx by 33.3% in the fourth quarter. Wells Fargo & Company MN now owns 11,208 shares of the company’s stock worth $54,000 after acquiring an additional 2,797 shares during the period. Institutional investors and hedge funds own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.